LQDA News and Press, Liquidia Technologies Inc. From 11/07/23

Liquidia Corporation (LQDA) is expected to report $-0.2 for Q3 2023

2023-11-06 13:24:50 ET Liquidia  ( NASDAQ: LQDA ) is scheduled to announce Q3 earnings results on Tuesday, November 7th, before market open. The consensus EPS Estimate is -$0.19 and the consensus Revenue Estimate is $4.33M (+35.3% Y/Y). Over the last 1 year, LQDA ...

2023-11-06 10:30:08 ET Major earnings expected before the bell on Tuesday include: Air Products and Chemicals ( APD ) Datadog ( DDOG ) D.R. Horton ( DHI ) Emerson Electric ( EMR ) Uber Technologies ( UBER ) For further details see: Notable...

MORRISVILLE, N.C., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its third quarter 2023 financial results on Tuesday, November 7, 2023. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a ...

2023-10-31 02:17:12 ET Summary I will recap the eleven partnership deals MannKind has been involved in over its operation as a corporation. I will share my opinion as it relates to the current status of these eleven partnerships. I will discuss why it is my opinion that MannKi...

2023-10-20 16:32:32 ET More on Liquidia Key Upcoming Catalysts Could Finally Turn Liquidia Profitable Liquidia Corporation (LQDA) Q2 2023 Earnings Call Transcript Liquidia adds second indication for Yutrepia marketing application Liquidia falls as U.S. appeal...

GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with initial terms expiring at Emergent’s 2024 Annual Meeting of Stockholders. Bo...

Sets PDUFA goal date of January 24, 2024 If approved, YUTREPIA would be indicated for treatment of both PAH and PH-ILD MORRISVILLE, N.C., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA)...

Asserts ‘793 patent in new litigation filed under Hatch-Waxman Act in response to Liquidia’s amendment to its NDA to add PH-ILD to YUTREPIA™ label Litigation is tied to same ‘793 patent previously ruled invalid by Patent Trial and Appeal Board (PTAB) MORRISVI...

2023-08-10 12:47:08 ET Liquidia Corporation (LQDA) Q2 2023 Earnings Conference Call August 10, 2023, 8:30 AM ET Company Participants Jason Adair - Chief Business Officer Roger Jeffs - Chief Executive Officer Rusty Schundler - General Counsel Mike Kaseta - Chi...